BIFIDO Co., Ltd. Sponsors the '2023 Korean Society of Food Science - BIFIDO Symposium'

Bifido Co., Ltd. (CEO Shin Yong-cheol) announced that it will sponsor the ‘2023 Korean Society of Food Science - BIFIDO Symposium’ (photo) hosted by the Korean Society of Food Science (President Lee Kwang-won), held on February 1 at the Korea Science and Technology Center in Yeoksam-dong, Seoul.

Under the theme “Microbiome for the Treatment and Prevention of Unresolved Intractable Diseases,” this symposium will introduce research results on the therapeutic and preventive effects of the microbiome on various diseases such as multiple viruses, brain function, rheumatoid arthritis, systemic sclerosis, and pulmonary fibrosis.

The event consists of two sessions. In the first session, Bifido’s Research Director Park Myung-soo will give a comprehensive presentation on Bifido’s microbiome research and development.

Following this, Professor Park Sung-hwan from the Catholic University College of Medicine will present research results on the therapeutic effects of the microbiome on rheumatoid arthritis; Professor Byun Sang-gyun from Yonsei University’s Department of Biotechnology will present research on the microbiome’s therapeutic effects on norovirus; and Professor Lee Sang-il from Gyeongsang National University College of Medicine will present research on the microbiome’s therapeutic effects on systemic sclerosis and pulmonary fibrosis.

In the second session, Professor Hong Sung-chul from Jeonbuk National University College of Medicine will present on the preventive and therapeutic effects of the microbiome on coronavirus; Professor Kim Sung-eun from Sookmyung Women’s University Department of Food and Nutrition will discuss the enhancement of efficacy and suppression of side effects of immune checkpoint inhibitors by the microbiome; and the final speaker, Professor Shin Dong-mi from Seoul National University Department of Food and Nutrition, will present research results on the microbiome’s effects on improving cognitive function.

Meanwhile, established in 1999, Bifido Co., Ltd. became the first microbiome company in 2018. It is a bio company listed on KOSDAQ through a technology special listing and holds proprietary patented strains BGN4, BORI, and AD011, which are the sixth in the world to receive FDA NDI (New Dietary Ingredient) and GRAS (Generally Recognized as Safe) certifications. The company is expanding its new pipeline through next-generation MAP (Microbiome Accelerating Platform) technology.

A Bifido representative stated, “With the world’s first FDA approval of a microbiome therapeutic for recurrent CDI in December last year, the likelihood of success for microbiome therapeutics for various diseases has significantly increased.” They added, “Our company has completed a CMO contract to actively advance clinical entry for a rheumatoid arthritis therapeutic, and we will continue to pursue clinical entry for the various pipelines introduced at this symposium.”